ESA Lawsuit Unsealed Against Amgen, Wyeth

Amgen, Wyeth and several other companies are facing a whistle-blower lawsuit over allegations that they engaged in off-label marketing of the erythropoiesis-stimulating agents (ESAs) Aranesp and Enbrel. The lawsuit had been sealed since it was filed in 2006. The U.S. District Court for the District of Massachusetts unsealed part of it last month, Wyeth says in its annual financial statement issued recently. The name of the whistle-blower remains sealed.
Washington Drug Letter